Savings and incentives associated with the utilization of biosimilars and unbranded biologics, including a look at how it impacts formulary access.Timothy O’Shea, PharmD, MS:The savings potential of driving to biosimilars can be significant. On average, we’re looking at [approximately] a 15% to 20% lower net cost when it comes to a biosimilar compared with [the] […]
